SCHEMBL3334937

SCHEMBL3334937

CNC(=O)c1cccc(-c2ccc3nc(N)nc(OC(C)C)c3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.46
DHFR P00374 1/20 0.45
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
CDK8 P49336 1/20 0.42
CYP17A1 P05093 1/20 0.41
CYP3A4 P08684 1/20 0.41
LCK P06239 1/20 0.41
IP6K1 Q92551 1/20 0.40
IP6K3 Q96PC2 1/20 0.40
IP6K2 Q9UHH9 1/20 0.40
PIK3CG P48736 1/20 0.39
NR4A2 P43354 1/20 0.39
ERN1 O75460 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
MAPT P10636 2/20 0.39
MMP9 P14780 1/20 0.39
ATM Q13315 1/20 0.39
CRBN Q96SW2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336495 0.90 MKNK1 (0.42) MKNK1MKNK2CDK8IP6K1IP6K3
SCHEMBL3335317 0.85 MAP4K4 (0.48) MAP4K4DHFRCDK8LCKIP6K1
SCHEMBL5129519 0.83 MGLL (0.40) CDK8MAPTLRRK2
SCHEMBL3331778 0.82 MKNK1 (0.39) MKNK1MKNK2MAPTATM
SCHEMBL3336523 0.81 IP6K1 (0.47) MAP4K4DHFRIP6K1IP6K3IP6K2
SCHEMBL3340183 0.81 TRIM58 (0.50) MAP4K4DHFRCDK8CRBNLRRK2
SCHEMBL3337252 0.81 SRC (0.51) MAP4K4DHFRMKNK1MKNK2CYP17A1
SCHEMBL3336047 0.81 RXRA (0.38) DHFRIP6K1IP6K3IP6K2RXRA
SCHEMBL3335363 0.79 JAK2 (0.51) IP6K1IP6K3IP6K2RXRARXRB
SCHEMBL3334631 0.78 MAP4K4 (0.53) MAP4K4DHFRMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 MAP4K4 2433/4885DHFR 703/4885MKNK1 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.